Render Target: STATIC
Render Timestamp: 2024-11-22T11:06:52.442Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-10-21 16:05:53.868
Product last modified at: 2024-11-20T17:15:08.474Z
View Featured Offers >>
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a
  1. Products /
  2. Primary Antibodies /
  3. Alzheimer's Disease Antibody Sampler Kit

Alzheimer's Disease Antibody Sampler Kit #9784

    Product Information

    Kit Usage Information

    Protocols

    Product Description

    The Alzheimer's Disease Antibody Sampler Kit provides an economical means of evaluating Alzheimer's disease-related signaling. The kit contains enough primary and secondary antibodies to perform two western blot experiments per primary antibody.

    Specificity / Sensitivity

    β-Amyloid (D54D2) XP® Rabbit mAb recognizes endogenous levels of total β-amyloid peptide (Aβ). The antibody detects several isoforms of Aβ, such as Aβ-37, Aβ-38, Aβ-39, Aβ-40, and Aβ-42. APP/β-Amyloid (NAB228) Mouse mAb detects endogenous levels of APP/β-Amyloid protein. Although this antibody recognizes both the phospho and non-phospho forms of the protein, it has been shown to prefer the phosphorylated form in some systems. BACE1 (D10E5) Rabbit mAb detects endogenous levels of total BACE1 protein. Phospho-GSK-3α (Ser21) (36E9) Rabbit mAb detects endogenous levels of GSK-3α protein when phosphorylated at Ser21, and does not detect GSK-3β when phosphorylated at Ser9. GSK-3α/β (D75D3) XP® Rabbit mAb detects endogenous levels of total GSK-3α and GSK-3β protein. The antigen is 100% conserved between GSK-3α and GSK-3β in humans, monkeys, mice, and rats. Neurofilament-L (C28E10) Rabbit mAb detects endogenous levels of total Neurofilament-L protein. α-Synuclein (Syn204) Mouse mAb detects endogenous levels of total synuclein protein. This antibody detects recombinant α but not β-synuclein (Giasson, B.I. et al., 2000). Tau (Tau46) Mouse mAb detects endogenous levels of total tau protein, and also cross-reacts with MAP2 at 280 kDa. This antibody is predicted to detect all six isoforms of tau based on the amino acid sequence.

    Source / Purification

    Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human ß-amyloid peptide (Aß), surrounding Glu450 of human Neurofilament-L protein, native bovine tau protein (carboxy terminus), a synthetic peptide corresponding to residues surrounding Asp490 of human BACE1 protein, human recombinant α-synuclein protein (amino terminus), ß-amyloid protein (amino terminus) (Lee et al., 2003), a synthetic peptide surrounding Gln269 of human GSK-3α protein, or a synthetic phosphopeptide corresponding to residues surrounding Ser21 of human GSK-3α protein

    Background

    Alzheimer's disease (AD) is one of the most common neurodegenerative diseases worldwide. Clinically, it is characterized by the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles, which results in neuronal dysfunction and cell death. Central to this disease is the differential processing of the integral transmembrane glycoprotein Amyloid β (A4) precursor protein (APP) that exists as several isoforms (1). The amino acid sequence of APP contains the amyloid domain, which can be released by a two-step proteolytic cleavage (1). β-secretase (BACE) is an aspartic acid proteinase that catalyses the initial step in APP processing by cleaving and releasing a soluble, extracellular APP-β (sAPPβ) ectodomain and generating a membrane-bound, carboxy-terminal fragment consisting of 99 amino acids (CTF99). Additional processing of CTF99 by γ-secretase generates the amyloid β-peptide (Aβ) that forms aggregates in the brains of AD patients. BACE is an attractive target for inhibitors in AD therapy since it catalyses the first and rate limiting step in amyloidogenic APP processing (2). Pro-BACE-1 is synthesized in the ER before it is transported to the trans-Golgi network to undergo maturation (3). The extracellular deposition and accumulation of the released Aβ fragments and an α-synuclein fragment known as the non- Aβ fragment, form the main components of amyloid plaques in AD. GSK-3α regulates the production of Aβ peptides. Administration of therapeutic concentrations of lithium, a GSK-3 inhibitor, attenuates Aβ production by specifically inhibiting the cleavage of APP by γ-secretase, thereby blocking accumulation of Aβ peptides in the brains of mice that overproduce APP (4). AD is also characterized by the presence of neurofibrillary tangles. These tangles are the result of hyperphosphorylation and oligomerization of the microtubule associated protein Tau and lead to apoptosis of the neuron. In particular, phosphorylation of Tau Ser396 by GSK-3

    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.